Podcasts about florida cancer specialists

In today's episode, we sat down with Liliana Bustamante, MD, and Jessica Stine, MD, to discuss their experiences as women in oncology. Dr Bustamante is a medical oncologist and hematologist at Florida Cancer Specialists & Research Institute in Tampa. Dr Stine is the medical director of Gynecologic Oncology at Florida Cancer Specialists & Research Institute. In our exclusive interview, Drs Bustamante and Stine discussed their unique journeys toward choosing careers in oncology, the emotional fulfillment of treating patients with cancer, the importance of mentorship between colleagues, and the evolving nature of work-life balance. They also emphasize the importance of honesty, peer support, and self-grace in navigating oncology careers.

Join Autumn Maloney, Director of Patient Financial Services at Florida Cancer Specialists & Research Institute, as she shares how eligibility and benefits automation has transformed their approach to prior authorizations and denials management. Learn how simplifying processes can reduce bad debt and enhance patient financial experience in the oncology space in oncology care.

Dr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, Dr Ticiana Leal from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Manish Patel from Florida Cancer Specialists & Research Institute in Sarasota, Florida, summarize recently presented advancements, including novel strategies, in the treatment of lung cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/OncologyToday24/NovelLung).

This week, we sit down with Layla Van Doren, MD, MBA, and Kristen Boykin, PharmD, BCOP, BCPS, to discuss IV iron therapy. Dr. Van Doren is a hematologist with Yale New Haven Health and Director of Education in the Adult Sickle Cell Program. Kristen is the Director of Pharmacy Operations at Florida Cancer Specialists and Research Institute.  This podcast episode is sponsored by Pharmacosmos Therapeutics Inc. Pharmacosmos Therapeutics Inc. is a U.S. specialty pharmaceutical company dedicated to providing patient care through the commercialization of Monoferric® (ferric derisomaltose) injection and through exceptional resources to support this treatment. We are the U.S. affiliate of the Denmark-based Pharmacosmos Group. Please visit us at www.monoferric.com to learn more.

Dr Manish Patel from the Florida Cancer Specialists & Research Institute in Sarasota, Florida, discusses drug development, early-phase clinical trials and the emerging field of B7-H3-targeted antibody-drug conjugates for solid tumors, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayB7H3ADCs23).

In this episode of Bladder Cancer Matters, host Rick Bangs chats with Dr. Elizabeth Guancial, a medical oncologist at Florida Cancer Specialists in Sarasota, Florida. They discuss the differences between receiving bladder cancer care in academic medical centers and community hospitals. Dr. Guancial is an expert because she has practiced in both types of institutions. Dr. Guancial shares that in academic medical centers, the focus is on teaching, research, and patient care, while community settings prioritize patient care. Community settings can often provide quicker care and more personalized attention, but academic medical centers may offer specialized procedures and access to clinical trials. Patients should consider factors such as the urgency of their condition, the need for specialized procedures, and the availability of clinical trials when deciding whether to seek care in a community or academic setting. It is also important for patients to feel comfortable with their healthcare providers and to seek second opinions if desired.

Dr Bradley J Monk from the Florida Cancer Specialists & Research Institute in West Palm Beach, Florida, discusses real-world patient cases and treatment strategies for ovarian cancer. CME information and select publications here (https://www.researchtopractice.com/MTPOvarian23/Part4).

Is obtaining real-time eligibility verification and benefits checks a bottleneck in your patient scheduling process? We're thrilled to host Autumn Maloney, Director of Patient Financial Services at Florida Cancer Specialists & Research Institute. With Aakarsh Sethi, Infinx Senior Product Manager for Patient Access Plus, she discusses the transformative impact of Infinx's eligibility verification and enhanced benefits check software on their organization. Brought to you by www.infinx.com

Today we are bringing you a conversation between 3 experts on precision medicine in non–small cell lung cancer (NSCLC). Martin Socinski, MD, executive director of the AdventHealth Cancer Institute, spoke with Martin Dietrich, MD, PhD, medical oncologist of Florida Cancer Specialists and Research Institute, and Joshua Sabari, MD, medical oncologist with NYU Langone Health Perlmutter Cancer Center and assistant progessor in the Department of Medicine at NYU Grossman School of Medicine. The topics of conversation for today's podcast include how precision medicine in NSCLC for patients with driver mutations, current immunotherapies for patients lacking driver mutations, and more.

Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Harold Burstein, Dr Asher Chanan-Khan, Dr Komal Jhaveri, Dr Brad S Kahl, Dr Alicia K Morgans, Dr Philip A Philip, Dr Gregory J Riely, Dr Matthew R Smith and Dr Heather Wakelee, including the following topics: Introduction (0:00) Non-Small Cell Lung Cancer Targeted Therapy — Dr Riely (4:09) Non-Small Cell Lung Cancer: Immunotherapeutic and Other Novel Strategies — Dr Wakelee (32:23) CME information and select publications

Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Harold Burstein, Dr Asher Chanan-Khan, Dr Komal Jhaveri, Dr Brad S Kahl, Dr Alicia K Morgans, Dr Philip A Philip, Dr Gregory J Riely, Dr Matthew R Smith and Dr Heather Wakelee, including the following topics: Introduction (0:00) Gastroesophageal Cancers — Dr Philip (1:42) Colorectal Cancer — Dr Bekaii-Saab (32:56) CME information and select publications

Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Harold Burstein, Dr Asher Chanan-Khan, Dr Komal Jhaveri, Dr Brad S Kahl, Dr Alicia K Morgans, Dr Philip A Philip, Dr Gregory J Riely, Dr Matthew R Smith and Dr Heather Wakelee, including the following topics: Introduction (0:00) Chronic Lymphocytic Leukemia (CLL): Considerations for Front-Line Treatment — Dr Kahl (1:48) Treatment of Relapsed/Refractory CLL; Novel and Investigational Strategies — Dr Chanan-Khan (35:38) Clinical Questions and Cases (49:58) CME information and select publications

Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Harold Burstein, Dr Asher Chanan-Khan, Dr Komal Jhaveri, Dr Brad S Kahl, Dr Alicia K Morgans, Dr Philip A Philip, Dr Gregory J Riely, Dr Matthew R Smith and Dr Heather Wakelee, including the following topics: Introduction (0:00) Role of Hormonal Therapy in Prostate Cancer Management — Dr Smith (1:50) Clinical Questions and Cases (13:18) Evidence-Based Use of Other Therapeutic Approaches in Metastatic Castration-Resistant Prostate Cancer — Dr Morgans (26:08) Clinical Questions and Cases (38:01) CME information and select publications

Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Harold Burstein, Dr Asher Chanan-Khan, Dr Komal Jhaveri, Dr Brad S Kahl, Dr Alicia K Morgans, Dr Philip A Philip, Dr Gregory J Riely, Dr Matthew R Smith and Dr Heather Wakelee, including the following topics: Introduction (0:00) ER-Positive Breast Cancer — Dr Burstein (3:57) Clinical Questions and Cases (16:47) Selection and Sequencing of Treatment for Relapsed ER-Positive Metastatic Breast Cancer — Dr Jhaveri (33:32) Clinical Questions and Cases (46:02) CME information and select publications

Lucio Gordan, MD, president and managing physician of Florida Cancer Specialists & Research Institute, discusses recently updated clinical guidelines from the National Comprehensive Cancer Network (NCCN) in multiple myeloma, which specifically discuss disease staging and risk stratification and advise clinicians on how to address 1q abnormalities.

CancerNetwork® spoke with experts across multiple disciplines about the far-reaching impacts of the ongoing shortages of chemotherapy drugs including carboplatin and cisplatin, and how practices may be able to mitigate these challenges in the short and long term.  Michael Ganio, PharmD, MS, BCPS, FASHP, described the causes of carboplatin and cisplatin being in short supply across the United States and how the FDA is working with Chinese manufacturers to import these chemotherapy agents. Ganio, senior director of Pharmacy Practice and Quality at the American Society of Health-System Pharmacists, stated that communication is paramount among all members of a care team to help prevent critical errors while treating patients with limited supplies of these drugs. He also spoke about how reaching out to local representatives may help address the issues resulting from these shortages. “Advocacy is needed,” Ganio said. “Our policymakers need to know that these shortages are having a real-world impact, and that they need to be addressed.” Brian Slomovitz, MD, MS, FACOG, spoke about how he is managing the ongoing shortages in the context of his gynecologic cancer care, including swapping one platinum-based drug for another during treatment. Slomovitz, a gynecologic oncologist, director of Gynecologic Oncology, and co-chair of the Cancer Research Committee at Mount Sinai Medical Center in Miami Beach, Florida and a professor of Obstetrics and Gynecology at Florida International University, also described the challenges many practices across the country have due to lacking platinum-based drugs altogether. “I know there are institutions that don't have [platinum-based chemotherapy],” Slomovitz said. “There are institutions that aren't able to give their patients the best standard-of-care therapy and aren't able to enroll patients in trials because of lack of therapy.”  Lucio N. Gordan, MD, addressed the financial impacts of these shortages, discussing how his practice has managed the rising prices of carboplatin and cisplatin in the country. Gordan, president and managing physician at Florida Cancer Specialists & Research Institute who sees patients in the state-wide practice's Gainesville Cancer Center, stated that efforts from major oncology organizations may help increase adequate access to chemotherapy drugs. “It's very important that the large practices and institutions in the country stay united,” Gordan said. “The Community Oncology Alliance [COA], American Society of Clinical Oncology [ASCO], and others are trying to push legislation that would protect the consumer, the patients, and us to make sure that we have a proven supply.” Don't forget to subscribe to the “Oncology On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

This week, we sit down with Joanna Fawzy Doran, Esq. and Amy Terhune, RPhT, CPhT, PACS, to discuss patient navigation and Triage Cancer. Joanna Fawzy Morales, Esq. is a cancer rights attorney and CEO of Triage Cancer, a national, nonprofit organization providing free education on practical and legal issues that impact individuals diagnosed with cancer and their caregivers through events, materials, and resources. Joanna has spent nearly 30 years working in the cancer community as an Adjunct Professor of Law and for the John Wayne Cancer Institute's Psychosocial Care Program. She has presented nearly one thousand seminars on employment, insurance, finances, and advocacy and co-authored a Cancer Rights Law book for the American Bar Association. In 2010, she was recognized by the Los Angeles Daily Journal as one of the Top 20 Attorneys in California Under the Age of 40.Amy Terhune, CPhT, RPhT, is a Prior Authorization Supervisor at Florida Cancer Specialists and Research Institute. She has been in pharmacy for 15 years, specializing in Oncology for the last four. Amy is an expert in obtaining prior authorizations for complex Oral oncolytic medications using up-to-date precision medicine to obtain payor approval rapidly, ensuring patients start therapy to avoid unnecessary delays in patient care.Resources discussed in this episode can be found here:https://TriageCancer.orghttps://TriageCancer.org/Eventshttps://CancerFinances.org  Practical Guide to Cancer Rights 

Florida Cancer Specialists & Research Institute's (FCS') Nathan Walcker, chief executive office at FCS, discusses some key strategic practices and initiatives in providing high quality community-based oncology care he has implemented at FCS.

In the first episode of our new podcast series, WCG Talks Trials, we are joined by three industry experts, Lisa Ballance from Virginia Commonwealth University, John Musser from Florida Cancer Specialists and Research Institute, and Dan Otap from Genentech, to discuss the topic of overcoming site challenges and addressing site burden.Listen in as we discuss the results of WCG's recently published 2023 Clinical Research Site Challenges Survey Report, gain insights from our guests on solutions their organizations have implemented to reduce site burden, and share perspectives on how sites, sponsors, and CROs can work to improve site and trial efficiency. Speakers: Sandy Smith, RN, MSN, AOCN  Senior Vice President, Clinical Solutions and Strategic Partnerships at WCG ClinicalLisa Richman Balance Associate Vice President for Research Strategy and Regulatory Affairs at Virginia Commonwealth University John Musser Senior Director, Clinical Research Administration at Florida Cancer Specialists & Research InstituteDan Otap Principal, Alliance and Partnerships Lead at Genentech

This week we sit down with Jennifer Byer, MD and Rachel Clark to discuss the Sugar Bloom Foundation. Dr. Jennifer Byer earned her medical degree and completed her Internal Medicine residency at the University of South Florida (USF) in Tampa, FL. In 2014, she was awarded a Fellowship in Hematology/Oncology at the Moffitt Cancer Center/University of South Florida. She is currently an oncologist at Florida Cancer Specialists and Research Institute. In honor of her mother, Sugar, and those courageously battling cancer, Rachel Clark established the Sugar Bloom Foundation. Tired of sterile waiting rooms, dreary hospital spaces, and anxious environments, Rachel embarked on a mission to fill these spaces with love, faith, and a profound sense of empathy and connection.Rachel lives in Vero Beach with her husband and two children. She and her husband own a veterinary clinic and founded Community Health Coalition, a charity that vaccinates canines in remote areas of Africa against rabies. 

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in multiple myeloma. Featuring perspectives from Dr Saad Zafar Usmani, including the following topics: BCMA-Directed Therapies for MM (0:00) Integration of Bispecific Antibody Treatment Approaches (4:05) CME information and select publications

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in endometrial cancer. Featuring perspectives from Dr Shannon Westin, including the following topics: “Biomarker”-Guided Therapy for EC (0:00) Targeted Therapy for EC; New Directions (18:24) CME information and select publications

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in breast cancer. Featuring perspectives from Drs Matthew Goetz and Ian Krop, including the following topics: HER2-Positive and HER2-Low Disease (0:00) ER-Positive, HER2-Negative Disease (31:55) CME information and select publications

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in hepatobiliary cancers. Featuring perspectives from Dr Ghassan Abou-Alfa, including the following topics: Treatment for Hepatocellular Carcinoma (0:00) Caring for Patients with Biliary Tract Cancers (11:16) CME information and select publications

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in lung cancer. Featuring perspectives from Drs Corey Langer and Christine Lovly, including the following topics: First-Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) in Patients without Targetable Mutations (0:00) Neoadjuvant and Adjuvant Treatment of Localized NSCLC (14:29) Targeted Treatment of Metastatic NSCLC (32:44) CME information and select publications

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in renal cell carcinoma. Featuring perspectives from Prof Thomas Powles, including the following topics: Optimal First-Line Therapy for Patients with Metastatic RCC (0:00) Treatment Approaches for Relapsed/Refractory Metastatic RCC (18:42) CME information and select publications

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in prostate and bladder cancers. Featuring perspectives from Drs Alicia Morgans and Evan Yu, including the following topics: Treatment for Prostate Cancer (0:00) Caring for Patients with Bladder Cancer (36:30) CME information and select publications

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in chronic lymphocytic leukemia and lymphomas. Featuring perspectives from Drs Ann LaCasce and Mitchell Smith, including the following topics: Hodgkin Lymphoma and CLL (0:00) Bispecific Antibodies, CAR T-Cell Therapy; Diffuse Large B-Cell Lymphoma (32:31) Treatment for Mantle Cell Lymphoma (53:23) CME information and select publications

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in melanoma. Featuring perspectives from Prof Georgina Long, including the following topics: Neoadjuvant and Adjuvant Therapy for Melanoma (0:00) Update on the Management of Metastatic Melanoma (19:23) CME information and select publications

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in gastrointestinal cancers. Featuring perspectives from Drs Wells Messersmith and John Strickler, including the following topics: Immunotherapy for Gastroesophageal Cancers; PARP Inhibitors in Pancreatic Cancer (0:00) HER2-Positive Gastroesophageal and Colorectal Cancer; Role of Circulating Tumor DNA/Minimal Residual Disease in Colorectal Cancer (20:21) Colorectal Cancer in Younger Patients; Tumor Microbiome (45:51) Neoadjuvant Therapy for Microsatellite Instability-High Gastroesophageal and Colorectal Cancer (47:53) Novel Agents in Pancreatic Cancer (53:14) CME information and select publications

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in ovarian cancer. Featuring perspectives from Dr David O'Malley, including the following topics: Primary Maintenance Therapy for OC (0:00) Current Management of Relapsed Disease (20:43) CME information and select publications

Proceedings from a daylong multitumor educational symposium in partnership with the Florida Cancer Specialists, including key clinical presentations and papers in chronic lymphocytic leukemia and lymphomas. Featuring perspectives from Drs Ann LaCasce and Mitchell Smith, moderated by Dr Neil Love.

Proceedings from a daylong multitumor educational symposium in partnership with the Florida Cancer Specialists, including key clinical presentations and papers in multiple myeloma. Featuring perspectives from Dr Saad Zafar Usmani, moderated by Dr Neil Love.

Proceedings from a daylong multitumor educational symposium in partnership with the Florida Cancer Specialists, including key clinical presentations and papers in breast cancer. Featuring perspectives from Drs Matthew Goetz and Ian Krop, moderated by Dr Neil Love.

Proceedings from a daylong multitumor educational symposium in partnership with the Florida Cancer Specialists, including key clinical presentations and papers in prostate and bladder cancers. Featuring perspectives from Drs Alicia Morgans and Evan Yu, moderated by Dr Neil Love.

Proceedings from a daylong multitumor educational symposium in partnership with the Florida Cancer Specialists, including key clinical presentations and papers in renal cell carcinoma. Featuring perspectives from Prof Thomas Powles, moderated by Dr Neil Love.

Proceedings from a daylong multitumor educational symposium in partnership with the Florida Cancer Specialists, including key clinical presentations and papers in hepatobiliary cancers. Featuring perspectives from Dr Ghassan Abou-Alfa, moderated by Dr Neil Love.

Proceedings from a daylong multitumor educational symposium in partnership with the Florida Cancer Specialists, including key clinical presentations and papers in gastrointestinal cancers. Featuring perspectives from Drs Wells Messersmith and John Strickler, moderated by Dr Neil Love.

Proceedings from a daylong multitumor educational symposium in partnership with the Florida Cancer Specialists, including key clinical presentations and papers in lung cancer. Featuring perspectives from Drs Corey Langer and Christine Lovly, moderated by Dr Neil Love.

Proceedings from a daylong multitumor educational symposium in partnership with the Florida Cancer Specialists, including key clinical presentations and papers in hepatobiliary cancers. Featuring perspectives from Dr Ghassan Abou-Alfa, moderated by Dr Neil Love.

Proceedings from a daylong multitumor educational symposium in partnership with the Florida Cancer Specialists, including key clinical presentations and papers in gastrointestinal cancers. Featuring perspectives from Drs Wells Messersmith and John Strickler, moderated by Dr Neil Love.

Proceedings from a daylong multitumor educational symposium in partnership with the Florida Cancer Specialists, including key clinical presentations and papers in ovarian cancer. Featuring perspectives from Dr David O'Malley, moderated by Dr Neil Love.

Proceedings from a daylong multitumor educational symposium in partnership with the Florida Cancer Specialists, including key clinical presentations and papers in endometrial cancer. Featuring perspectives from Dr Shannon Westin, moderated by Dr Neil Love.

Proceedings from a daylong multitumor educational symposium in partnership with the Florida Cancer Specialists, including key clinical presentations and papers in gastrointestinal cancers. Featuring perspectives from Drs Wells Messersmith and John Strickler, moderated by Dr Neil Love.

Proceedings from a daylong multitumor educational symposium in partnership with the Florida Cancer Specialists, including key clinical presentations and papers in hepatobiliary cancers. Featuring perspectives from Dr Ghassan Abou-Alfa, moderated by Dr Neil Love.

Proceedings from a daylong multitumor educational symposium in partnership with the Florida Cancer Specialists, including key clinical presentations and papers in melanoma. Featuring perspectives from Prof Georgina Long, moderated by Dr Neil Love.

Host Dr. John Sweetenham, of the UT Southwestern Harold C. Simmons Comprehensive Cancer Center, and Dr. Eduardo Sotomayor, director of the cancer institute at Tampa General Hospital, discuss the impact of Hurricane Ian on cancer care in Florida, and the importance of disaster preparedness to protect patients and clinicians in regions prone to natural disasters.   TRANSCRIPT Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, the associate director for Clinical Affairs at UT Southwestern's Harold C. Simmons Comprehensive Cancer Center, and host of the ASCO Daily News podcast. Hurricane Ian, a large and destructive Category 4 hurricane, has caused fatalities and widespread damage in Florida after causing huge destruction in Cuba. Communities in the hardest-hit areas have been destroyed, and hospitals across the state have been forced to evacuate patients. Today, I will be speaking with Dr. Eduardo Sotomayor, the director of the Cancer Institute at Tampa General Hospital, about the impact of the hurricane on cancer care. Our full disclosures are available on the transcript of this episode, and disclosures relating to all episodes of the ASCO Daily News podcast are available on our transcripts at asco.org/podcasts. Dr. Sotomayor, thanks for being on the podcast today. Dr. Eduardo Sotomayor: Thank you, John, and the ASCO Daily News Podcast, for having me. Dr. John Sweetenham: To begin with, Dr. Sotomayor, could you tell us a little about how Hurricane Ian impacted cancer care at your institution, and how soon do you think you'll have all of your cancer services restored? Dr. Eduardo Sotomayor: Thank you for the opportunity to talk to you about the effect of Hurricane Ian on the state of Florida. But before we start, I would like to say that our thoughts and our prayers are for those Florida citizens who were severely affected by this hurricane, in particular, our cancer patients and their caregivers. So, Tampa General Hospital is located on Davis Islands. So, we were at high risk for having inundation, major destruction, and disruptions in cancer care if the hurricane hit us directly. We were blessed that at the last minute, the hurricane changed its path. But it's important to emphasize all of the preparation that took place, starting seven days before the potential landfall of the hurricane in the state of Florida. This started at the highest levels of the hospital, with the senior leaders getting together as well as the leaders of the cancer institute. We have different scenarios that we call scenario A, B, and C. So, scenario A was the worst-case scenario that we would have a direct hit, then one or two floors of the cancer institute and the hospital would be under water. So, for that scenario, we knew that we needed to be ready to move cancer care to other facilities that Tampa General has inland in areas called Riverview and Brandon. So, scenario C is the scenario that fortunately for us, was the scenario that we dealt with during the storm. We didn't have a direct hit; we had only minimal damage, and we were able to reopen our doors 48 hours after the storm hit Florida. Important to mention also is that during those 48 hours, there was significant disruption in cancer care. In the inpatient service, we had to decrease the number of inpatients to keep those patients that really needed to be in the hospital. We closed all our outpatient facilities and therefore needed to call every patient to let them know about the cancellation of appointments, but also re-scheduling those appointments for the days after the storm has passed. As I said, again, we were among the lucky cancer centers in the state of Florida, but south of us, there were hospitals and community oncology practices that were severely affected by Hurricane Ian. Dr. John Sweetenham: So, it sounds to some extent, Dr. Sotomayor, as if your institution kind of dodged a bullet, although clearly people south of you were very badly affected. But I'm assuming that there had been some disruptions to care for your patients. Can you comment a little on that, and what you're doing to address the disruptions to care, assuming that you experienced some, even though you didn't take a direct hit. Dr. Eduardo Sotomayor: What we have learned from this experience is that preparation is extremely important. Within 24 hours, we created a command center, an operations team, our logistics team, safety team, and we started canceling those appointments that were not critical. When we knew that the hurricane was coming in our direction, then we had to cancel all of our operations. But then we had meetings twice a day with different members of our team to start making phone calls also regarding cancellation of appointments. And then, as the days passed, we started to adapt our plans and starting calling back patients. What is important, I think a silver lining of the COVID-19 pandemic, has been the availability of telehealth, of easy communication with patients. I think that patients are now savvier with managing telehealth. So, the days after the hurricane hit us, we had some patients that had to come back to receive chemotherapy infusions or radiation, but the large priority of patients were able to manage via telehealth. Dr. John Sweetenham: Yes. Thank you. I know one of the questions that I was going to ask you a little later on was whether the telehealth infrastructure that was developed during the COVID-19 pandemic was helpful in response to the hurricane, and clearly from your comments, it has made it easier in terms of patients' familiarity with the platform and so on. So, that's good to know. Dr. Eduardo Sotomayor: Right. And also, just to add to that is that technology before the COVID-19 pandemic, when we were facing a similar situation. Basically, all our call centers would be closed. So, these days we have technology in which employees or members of our team that were receiving or making phone calls, now can do through through special apps in case the internet goes down or electricity goes down. Still, now there are systems that can allow temporary communication with patients in a timelier way. Dr. John Sweetenham: Yeah, that's very reassuring. The Florida Hospital Association has said that many hospitals are feeling capacity pressure. Can you comment on what the Tampa General Hospital is able to help by perhaps offloading other institutions that were badly damaged in the storm, particularly those in the Southwest of Florida? Dr. Eduardo Sotomayor: Yeah, that's a very important question. I think that when we knew that we would be okay and there would not be a significant impact of the hurricane on our facilities, we changed our course and started calling our partners in the oncology community, private practice groups, Florida Cancer Specialists that have offices and provide cancer care in those areas that were severely affected by the hurricane. We are working together. One of the things that I have learned is that a significant percentage of cancer care is performed in the community. Communities were affected by this hurricane and therefore I think it is important to keep that open communication between academic centers and oncology practice in the community. With reference to your question, Tampa General has six helicopters; it has a command center and as soon as it was safe for our helicopters to travel, they went to these affected areas. There were hospitals near our region that didn't have electricity or water. I am proud of the service provided by Tampa General Hospital to other hospitals and cancer care communities that were severely affected by the hurricane. I think so far, we were able to transfer between 50 to 70 patients who were in critical condition and needed to be removed from those areas that were significantly affected by the hurricane. And I have to say, Tampa General Hospital is just one of the hospitals that responded; all of the hospitals in the state of Florida joined a forces to help our patients in general during these difficult times. Dr. John Sweetenham: Yeah, it's certainly great to hear of the oncology community and healthcare community in general coming together to overcome the challenges for so many of these patients. You know, one of the challenges that occurs to me, which might be an issue for you because of your increased patient volumes, as well as for those centers that are more directly affected by the hurricane, and that's the issue of supply chain and availability of medicines, and particularly chemotherapy and other antineoplastic drugs. Can you comment on whether you are experiencing any supply chain issues with medicines, or whether you're aware of other organizations in the southern part of Florida who are having those challenges at the moment? Dr. Eduardo Sotomayor: So, there are two answers to your question; if we are lucky to be in urban communities, I think that the supply chain was not significantly affected, but the problem has been in the rural communities in Florida. And unfortunately, in addition to the areas near the ocean, including Fort Myers, Naples, and Port Charlotte, the track of the hurricane through Florida affected the rural communities. And in those rural communities the problem was flooding, several trees went down, access in those areas was problematic, and they are still dealing with significant issues in the supply chain. What we are doing as are all the other big centers, is  trying to do our best to either provide those supplies to these affected areas or to transfer some of the patients from those areas to, I would say, urban hospitals that have more capacity. Dr. John Sweetenham: So, this raises, I think, a really important issue. We know that very typically underserved communities are disproportionately impacted when there are natural disasters. And to your point, it's clear that you've seen the potential for significant disruption to rural versus urban communities as a result of the hurricane. Do you have any other thoughts or maybe any other examples of how disproportionate care may have arisen because of the effects on underserved communities? Dr. Eduardo Sotomayor: Even before any natural disasters, rural communities-- and I want to focus on rural communities in the state of Florida because there is a significant number of Floridians that live in rural communities. And if you look at the incidence of cancer and mortality associated with cancer in those rural communities, it is greater than the mortality that occurs in urban areas or big cities. So, number one. And there are several issues; there is transportation, access to care, very few oncology providers in those areas. So, even before the natural disaster that just happened, those communities were significantly disadvantaged. And unfortunately, not only the hurricane affected those rural areas, but now I would say the few organizational capabilities that they have have been further impacted. So therefore, when we think about the impact of the hurricane in the state of Florida, we should also be thinking about our rural communities. They are the ones that are going to take longer, perhaps months, or even a year, to recover from the significant damage that Hurricane Ian has imposed upon those communities. Dr. John Sweetenham: Thanks. Switching gears a little, are you concerned about the disruption of research and clinical trials in parts of Florida in the months ahead? I'm just thinking with issues such as-- you know, initially it will be scheduling of treatments, perhaps the transportation disruption, and so on. Do you see these as being potential threats to clinical trial activity in the state for the coming months, and possibly years? Dr. Eduardo Sotomayor: So again, I think that clinical trials in big centers, in urban areas are going to be able to recover relatively quickly. I mean, for instance, our clinical trials operation is back to normal, and was not affected. So, there is a big community oncology practice in the state of Florida, Florida Cancer Specialists, especially if they have active clinical trials, but they have locations in several of the areas that were significantly affected by the hurricane. So, I think in those areas, it is going to take time to recover. But in my early conversations with our colleagues, Florida Cancer Specialists especially, they're going to be moving some clinical trials operations from those affected areas to areas that are fully functional. But definitely, there is going to be a disruption, yes. And unfortunately, that disruption is going to affect those patients enrolled in clinical trials that live in underserved areas, and in particular, those who live in rural areas because access to transportation is going to be a significant problem for them. Dr. John Sweetenham: Yeah, absolutely. I think is one of the consequences of what the emerging climate changes that we've been seeing over many years now, and certainly, there has been a significant interest in the literature, and indeed, on previous ASCO Daily News podcasts regarding the impact of climate change on cancer care. And perhaps, the most immediate example of that is in terms of disaster preparedness of cancer centers. Certainly, that has been tested for you and for other centers in Florida in the last couple of weeks. How would you assess the readiness of your cancer centers to respond to disasters of this scale? Do you think there are areas of care that you've now learned need more attention, just as a direct consequence of this most recent hurricane? Dr. Eduardo Sotomayor: So, I think it's going to be location-dependent. You know, Florida is a big state. For us and other centers that are in the islands, the surge was probably the major threat for us. I mean, there is a technology now called AquaFence. So basically, there are panels that will help you, to be able to give you time to evacuate or to protect the lower floors of the cancer center of the TGH hospital as a whole. It's called AquaFence. So, we install those panels around the whole hospital, and I think that's one of the technologies. And we are going to see more and more of those technologies to try to protect or minimize the potential damage that a hurricane can cause. I mean, my prediction is that it's going to be able to support a hurricane category two, three, or even four, but you know, five - time will tell. So, we need to start thinking more about technology, that's in our case. So, there are other cancer centers that are inland in which the problem for them is going to be flooding. So, one lesson that we have learned is, there has been constant communication between all the cancer centers in this region. In the academic institutions, the University of Miami, Florida, us, Moffitt Cancer Center, but also in the community - Florida Cancer Specialists, especially, community oncology practices. And I think that if you ask me, "What would be the next step?" It will be to foster stronger communication, a stronger collaboration that involves also our community oncology practices because as you know, John, most of the cancer care now is happening close to home. Dr. John Sweetenham: Well, thanks for that. I think that's such an important message, and I should add for our listeners that you can find information about disaster resources for care providers and patients on the ASCO website, at: asco.org. Dr. Sotomayor, I just want to thank you again for giving us your time today at what must be a really busy time for you all and would like to wish you and our many colleagues in the region, especially those in the hardest hit areas of southwest Florida, all the best during difficult and uncertain times as they try to recover from the hurricane. Dr. Eduardo Sotomayor: There are so many heroes here - talking about cancer care, you know, oncologists, nurses, APPs, MAs - they left their families at home and they went and they stayed with patients. So, I am proud to say that most of them, they offered to go there. We didn't need to say you, and you, and you. And I want to thank all of those, you know, our colleagues, providers, all the team members in all the hospitals, big, medium size, also small, in the state of Florida, that they left their loved ones to be support and take care of our patients. Dr. John Sweetenham: Certainly heartwarming to hear about that kind of response. And thanks again to you, Dr. Sotomayor. And thank you to our listeners for your time today. If you value the insights that you hear on ASCO Daily News podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy, should not be construed as an ASCO endorsement. Follow today's speakers: Dr. John Sweetenham @JSweetenhamMD Dr. Eduardo Sotomayor Tampa General Cancer Institute   Want more related content? Listen to our podcast on climate change and cancer: Climate Change and Cancer   Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn   Disclosures: Dr. John Sweetenham: Consulting or Advisory Role: EMA Wellness Dr. Eduardo Sotomayor: Consulting or Advisory Role: Seattle Genetics, Genentech/Roche, Celgene, Kite Pharma, Bayer, AstraZeneca, Pharmacyclics Speakers' Bureau: Seattle Genetics, Pharmacyclics

It takes more than money to attract and motivate great employees. It's vital that leaders communicate a bigger purpose that your team can follow. This keeps your team aligned and focused even in the midst of challenging times. I host Mark Moch, Chief information Officer of American Oncology Network, the fastest growing network of community oncology practices delivering local access to cancer care with over 70 locations. He shares  why leading with a bigger purpose is so important and his two favorite ideas for your team. Mark's also served as a senior leader at Florida Cancer Specialists & Research Institute as well as Promise Healthcare both based in Florida. Originally from Poland, he says that he and his wife “won the green card lottery and wanted to have an adventure in the USA”. LinkedIn Profile https://www.linkedin.com/in/markmoch/ (https://www.linkedin.com/in/markmoch/) Company Link: https://www.aoncology.com/ (https://www.aoncology.com/) What You'll Discover in this Episode: Mark's inspiring journey from literature teacher in Poland to CIO of a thriving US company. Why teaching prepared him C-Suite. Leading on the cutting edge of where healthcare and technology intersect. Advice of leaders who are balancing a big vision with day–to-day goals What literature teaches leaders about self-reflection. Why your purpose should drive your focus. What Mark learned from his first big leadership win. The importance of having “new collar” workers in your workforce. Resources: Thomas Mann Hesey Taikchoksy Leaders Start with Why, Simon Sinek Drive, Daniel Pink Code Breakers Rise of the Data Cloud The Alchemist,Paulo Coehlo Lead the Team Podcast episode with IBM CHRO, Nickel LaMoreaux Quotes: "My whole Leadership style is built around my team – 100% believer in servant leadership. Tough but compassionate. My team is the most important in everything I do at work. It is a base everything else comes out of. I am a dreamer and think that technology will solve a lot of healthcare problems in future. We are on the verge of breakthrough and we are all responsible to push it forward." ----- Connect with the Host, #1 bestselling author Ben Fanning https://www.benfanning.com/speaker/ (Speaking and Training inquires) https://followbenonyoutube.com (Subscribe to my Youtube channel) https://www.linkedin.com/in/benfanning/ (LinkedIn) https://www.instagram.com/benfanning1/ (Instagram) https://twitter.com/BenFanning1 (Twitter)

“Sometimes in our daily routine of taking care of patients, it's more about looking at the treatment side effects. But look at those wide array of symptoms that can present with an oncologic emergency. They will kind of sneak up on you, and as an oncology nurse, we all need to be educated about them,” ONS member Diane Cope, PhD, APRN, BC, AOCNP®, director of nursing and oncology nurse practitioner at Florida Cancer Specialists and Research Institute in Fort Myers told Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS. During this episode, Cope explained the clinical manifestations associated with syndrome of inappropriate antidiuretic hormone (SIADH) and its medical and nursing interventions. The episode is part of a series about oncologic emergencies; the previous episodes are linked below. You can also earn free NCPD contact hours by completing the evaluation linked below. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by July 1, 2024. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Episode Notes Check out these resources from today's episode: Complete this evaluation for free NCPD. Previous Oncology Nursing Podcast episodes on oncologic emergencies ONS Huddle Card™: Hormone Therapy ONS books: Understanding and Managing Oncologic Emergencies: A Resource for Nurses (third edition) Clinical Manual for the Oncology Advanced Practice Nurse (fourth edition) Clinical Journal of Oncology Nursing articles: STAT: Syndrome of Inappropriate Antidiuretic Hormone (SIADH) Syndrome of Inappropriate Antidiuretic Hormone Secretion in Malignancy: Review and Implications for Nursing Management Hyponatremia and SIADH: A Case Study for Nursing Consideration To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.

COR2ED Medical Education: In this podcast, Beth Wittmer RN, Director of Care Management at Florida Cancer Specialists, USA and Prof. Hans Prenen, GI Medical Oncologist from Antwerp University Hospital, Belgium, discuss the management of dermatological side effects that patients may experience when receiving treatment with multikinase inhibitors, such as regorafenib, sunitinib, cabozantinib amongst others. They discuss the different skin related side effects that a patient may experience such as hand foot skin reactions, rash, hair and nail changes as well as mucosal changes. The experts note that these side effects can affect a patient emotionally and impair their quality of life so the objective is to effectively treat and manage side effects and to keep patients on the treatment, whilst maintaining reasonable quality of life. They discuss preventative measures, the importance of discussing potential side effects with the patient and when to involve a dermatologist as well as dose management strategies to enable the patient to stay on their cancer treatment.

As part of its Between the Lines™ video series, CancerNetwork® spoke with Liliana Bustamante, MD, hematologist and medical oncologist at Florida Cancer Specialists in Fort Myers, Florida and Richard Kim, MD, service chief of Medical Gastrointestinal Oncology and senior member in the Gastrointestinal Oncology Department at the Moffitt Cancer Center in Tampa, Florida, about the prognostic potential of circulating tumor DNA (ctDNA) as a biomarker for patients with oligometastatic colorectal cancer. In the video series, Bustamante and Kim discussed the following: ·      Presentation: ctDNA Assays For Patients With CRC Undergoing Resection of Metastases ·      Key Takeaways: ctDNA Assays For Patients With CRC Undergoing Resection of Metastases ·      ctDNA as a Biomarker in CRC ·      ctDNA Assays in CRC: Interpreting Clinical Findings ·      ctDNA Assays in CRC: Impact on Clinical Practice ·      Next Steps in Using ctDNA as a Biomarker in CRC ·      Recap: Prognostic Potential of ctDNA for Oligometastatic Colorectal Cancer To watch more videos in CancerNetwork®'s Between the Lines™ series, visit cancernetwork.com/between-the-lines. Don't forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

In this episode, a part of our biomarker testing series, we are joined by Dr. Manish Patel, Director of Drug Development for Florida Cancer Specialists, to talk about biomarker testing in the community oncology setting - from the importance of emerging biomarkers to basket and umbrella trial designs.If you have any questions for today's guest or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com.The content and information contained in this podcast is sponsored by Elevation Oncology. This podcast is for educational, and informational purposes only. This podcast does not constitute medical or other professional advice or services. No person should act or refrain from acting on the basis of content provided in any podcast or website without first seeking appropriate medical advice and counseling. The opinions expressed in this podcast are the opinions of the individual and may not reflect the opinions of IntrinsiQ or Elevation Oncology.

In this episode, a part of our biomarker testing series, we are joined by Dr. Manish Patel, Director of Drug Development for Florida Cancer Specialists, to talk about biomarker testing in the community oncology setting - from the advantages and disadvantages of liquid biopsies to the benefits of ordering test panels.If you have any questions for today's guest or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com.The content and information contained in this podcast is sponsored by Elevation Oncology. This podcast is for educational, and informational purposes only. This podcast does not constitute medical or other professional advice or services. No person should act or refrain from acting on the basis of content provided in any podcast or website without first seeking appropriate medical advice and counseling. The opinions expressed in this podcast are the opinions of the individual and may not reflect the opinions of IntrinsiQ or Elevation Oncology.

In this episode, a part of our biomarker testing series, we are joined by Dr. Manish Patel, Director of Drug Development for Florida Cancer Specialists, to talk about the basics of biomarker testing – from identifying common testing approaches to comparing DNA and RNA sequencing. If you have any questions for today's guest or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com. The content and information contained in this podcast is sponsored by Elevation Oncology. This podcast is for educational, and informational purposes only. This podcast does not constitute medical or other professional advice or services. No person should act or refrain from acting on the basis of content provided in any podcast or website without first seeking appropriate medical advice and counseling. The opinions expressed in this podcast are the opinions of the individual and may not reflect the opinions of IntrinsiQ or Elevation Oncology.

ONS member Diane Cope, PhD, ARNP-BC, AOCNP®, director of nursing and oncology nurse practitioner at Florida Cancer Specialists and Research Institute in Fort Myers, joins Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss tumor lysis syndrome and its current prevention and management strategies. This episode is part of a series about oncologic emergencies; the previous episodes are also linked in the episode notes. The advertising messages in this episode are paid for by clonoSEQ.  Episode Notes  Check out these resources from today's episode:  NCPD contact hours are not available for this episode.  Previous Oncology Nursing Podcast episodes on oncologic emergencies  ONS Voice article: What Oncology Nurses Need to Know About Tumor Lysis Syndrome  Clinical Journal of Oncology Nursing article: Preventing Tumor Lysis Syndrome: Two Case Studies of Unexpected Outcomes  Clinical Journal of Oncology Nursing article: STAT: Tumor Lysis Syndrome  ONS book: Understanding and Managing Oncologic Emergencies: A Resource for Nurses third edition   ONS course: Essentials in Oncologic Emergencies for the Advanced Practice Provider   ONS course: Treatment and Symptom Management—Oncology RN  JAMA Oncology patient page on tumor lysis syndrome  Medscape information on managing tumor lysis syndrome  UpToDate information on preventing and treating tumor lysis syndrome  To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. 

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in acute myeloid leukemia, breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Neeraj Agarwal, Tanios Bekaii-Saab, Kristen Ciombor, Brad Kahl, Mark Levis, Ann Partridge, Mark Pegram, Daniel Petrylak, Noopur Raje, David Sallman, Lecia Sequist, David Spigel, Saad Zafar Usmani and Andrew Zelenetz.

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in acute myeloid leukemia, breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Neeraj Agarwal, Tanios Bekaii-Saab, Kristen Ciombor, Brad Kahl, Mark Levis, Ann Partridge, Mark Pegram, Daniel Petrylak, Noopur Raje, David Sallman, Lecia Sequist, David Spigel, Saad Zafar Usmani and Andrew Zelenetz.

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in acute myeloid leukemia, breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Neeraj Agarwal, Tanios Bekaii-Saab, Kristen Ciombor, Brad Kahl, Mark Levis, Ann Partridge, Mark Pegram, Daniel Petrylak, Noopur Raje, David Sallman, Lecia Sequist, David Spigel, Saad Zafar Usmani and Andrew Zelenetz.

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in acute myeloid leukemia, breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Neeraj Agarwal, Tanios Bekaii-Saab, Kristen Ciombor, Brad Kahl, Mark Levis, Ann Partridge, Mark Pegram, Daniel Petrylak, Noopur Raje, David Sallman, Lecia Sequist, David Spigel, Saad Zafar Usmani and Andrew Zelenetz.

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in acute myeloid leukemia and myelodysplastic syndromes. Featuring perspectives from Drs Mark Levis and David Sallman, including the following topics: Introduction Challenge of New Treatment Options for AML; Role of CPX-351 — Dr Peles Hypomethylating Agents/Venetoclax: Appropriate Candidates, Tolerability and Dose Adjustments — Dr Kumar Personal Experience with Administering Azacitidine/Venetoclax — Dr Choksi Approach to Treatment-Associated Adverse Events After the First Cycle of Venetoclax/HMA in Patients with AML Chalk Talk — Dr Sallman (Part 1) Case: A woman in her late 60s with AML — Dr Gandhi Appropriate Use of Antifungal Agents for Patients Receiving Venetoclax — Dr Apuri Role of FLT3 and IDH1/2 Inhibitors for Patients Who Are Ineligible for Intensive Induction Therapy — Dr Peles Up-Front Management of AML in Older Patients with an IDH Mutation Who Are Not Eligible for Intensive Therapy Chalk Talk — Dr Sallman (Part 2) Management of Secondary AML in Younger Patients Chalk Talk — Dr Levis (Part 1) Case: A woman in her early 80s initially treated for idiopathic thrombocytopenic purpura — Ferdy Santiago, MD Case: A woman in her late 80s with low-grade myelodysplastic syndromes with ringed sideroblasts — Dr Apuri Luspatercept for Patients with Lower-Risk Myelodysplastic Syndromes Chalk Talk — Dr Levis (Part 2) CME information and select publications  

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in multiple myeloma. Featuring perspectives from Drs Noopur Raje and Saad Zafar Usmani, including the following topics: Introduction Front-Line Treatment for Transplant-Ineligible Patients; Incorporation of CAR T-Cell Therapy — Dr Choksi Up-Front Management of Multiple Myeloma in Young Patients with Adverse Cytogenetics Chalk Talk — Dr Raje Efficacy and Tolerability of Subcutaneous versus IV Daratumumab in Patients with Multiple Myeloma Chalk Talk — Dr Usmani (Part 1) Substitution of Isatuximab for Daratumumab; Role of Transplant; Role of Minimal Residual Disease — Dr Kumar Nonresearch Role of Venetoclax for Patients with R/R Multiple Myeloma and t(11;14) or Bcl-2 Overexpression Chalk Talk — Dr Usmani (Part 2) Case: A man in his mid-60s with relapsed/refractory multiple myeloma with t(4:14) and del(17p) — Dr Usmani Comment on Dr Usmani's 64-Year-Old Man: High-Risk Cytogenetics — Paul G Richardson, MD and Peter Voorhees, MD Comment on Dr Usmani's 64-Year-Old Man: CAR T-Cell Therapy — Drs Richardson and Voorhees CAR T-Cell Therapy Investigational Strategies Chalk Talk — Dr Raje Investigational Bispecific Antibodies for R/R Multiple Myeloma Chalk Talk — Dr Usmani CME information and select publications

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in chronic lymphocytic leukemia and lymphomas. Featuring perspectives from Drs Brad Kahl and Andrew Zelenetz, including the following topics: Introduction Case: A man in his early 70s with relapsed mantle cell lymphoma — Zanetta S Lamar, MD Chimeric Antigen-Receptor (CAR) T-Cell Therapy and Use in Elderly Patients — Dr Gandhi Optimal Second-Line Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) After R-CHOP Chalk Talk — Dr Zelenetz Sequencing Tafasitamab/Lenalidomide with Other Novel Agents for Relapsed/Refractory (R/R) DLBCL Chalk Talk — Dr Kahl Case: A woman in her early 20s with mixed cellularity classical Hodgkin lymphoma — Dr Peles Hodgkin Lymphoma Chalk Talk — Dr Kahl Treatment of p53-Negative versus p53-Positive Disease — Dr Kumar Selection of Front-Line BTK Inhibitors for Patients with Chronic Lymphocytic Leukemia Chalk Talk — Dr Zelenetz Combining Venetoclax with an Anti-CD20 Antibody for Relapsed Chronic Lymphocytic Leukemia Chalk Talk — Dr Kahl Case: A man in his early 80s with Grade I-II follicular lymphoma — Dr Shameem Treatment Options for Relapsed Follicular Lymphoma — Dr Peles Role of Tazemetostat in Therapy for Relapsed Follicular Lymphoma with and without an EZH2 Mutation Chalk Talk — Dr Zelenetz CME information and select publications

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in genitourinary cancers. Featuring perspectives from Drs Neeraj Agarwal and Daniel Petrylak, including the following topics: Introduction Case: A woman in her early 50s with metastatic renal cell carcinoma with rhabdoid features — Dr Kumar Comparing First-Line Treatment Options for Metastatic Renal Cell Carcinoma Chalk Talk — Dr Petrylak Second-Line Treatment of Metastatic Renal Cell Carcinoma After Progression on Checkpoint Inhibitor-Based Therapy Chalk Talk — Dr Agarwal Case: A healthy man in his late 80s with locally recurrent castration-resistant prostate cancer (CRPC) — Dr Guancial Case: A man in his mid-80s with metastatic CRPC and a somatic BRCA2 mutation — Dr Zafar 177Lu-PSMA-617 in Metastatic CRPC Chalk Talk — Dr Agarwal Case: A man in his early 60s with metastatic CRPC and an ATM mutation — Dr Shameem Genomic Testing and PARP Inhibition for Metastatic Prostate Cancers with a BRCA Mutation Chalk Talk — Dr Petrylak Case: A woman in her late 70s with non-muscle-invasive urothelial bladder cancer — Dr Gandhi Case: A man in his late 60s with localized urothelial bladder carcinoma (UBC) — Dr Choksi Case: A woman in her early 70s with high-TMB muscle-invasive UBC and high-PD-L1 expression — Dr Guancial Genomic Testing and PARP Inhibition for Metastatic Prostate Cancers with a BRCA Mutation Chalk Talk — Dr Petrylak Sequencing Enfortumab Vedotin and Other Targeted Therapies for Metastatic UBC Chalk Talk — Dr Agarwal CME information and select publications

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in lung cancer. Featuring perspectives from Drs Lecia Sequist and David Spigel, including the following topics: Introduction Case: A woman in her early 70s with microsatellite stable metastatic adenocarcinoma of the lung and a HER2 mutation, PD-L1 TPS 0% — Dr Zafar Case: A man in his mid-80s with localized adenocarcinoma of the lung and an EGFR exon 19 deletion — Dr Gandhi Case: A woman in her late 70s with metastatic adenocarcinoma of the lung, somatic BRCA2 and KRAS G12C mutations and high tumor mutation burden (TMB) — Kapisthalam (KS) Kumar, MD Targeted Therapy for Lung Cancer Chalk Talk — Dr Spigel Case: A man in his mid-60s with Stage IIIA (8-cm, node-negative) adenocarcinoma of the lung — Shachar Peles, MD Case: A man in his mid-50s with Stage IIIA adenocarcinoma of the lung — Dr Choksi Case: A woman in her mid-60s with metastatic adenocarcinoma of the lung, PD-L1 56% — Dr Gandhi First-Line Treatment of PD-L1-Negative Metastatic NSCLC without a Targetable Mutation Chalk Talk — Dr Sequist Selecting Patients with Localized NSCLC for Adjuvant Immunotherapy Chalk Talk — Dr Spigel Case: A man in his early 50s with extensive-stage small cell lung cancer (SCLC) — Dr Apuri Case: A man in his mid-60s with extensive-stage SCLC and concurrent prostate cancer — Dr Gandhi CME information and select publications

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in gastrointestinal cancers. Featuring perspectives from Drs Tanios Bekaii-Saab and Kristen Ciombor, including the following topics: Introduction Case: A woman in her early 70s with metastatic hepatocellular carcinoma (HCC) — Dr Peles Treatment Options for Child-Pugh B HCC — Dr Choksi First-Line Treatment for Advanced HCC with Child-Pugh B or C Cirrhosis — Dr Bekaii-Saab Second-Line Systemic Treatment for Advanced HCC After Atezolizumab/Bevacizumab — Dr Ciombor Case: A woman in her early 60s with microsatellite instability-high Stage IV colorectal cancer (CRC) and a BRAF V600E mutation — Ina J Patel, DO Case: A woman in her late 50s with microsatellite stable metastatic CRC and a KRAS G12C mutation — Dr Apuri First-Line Immunotherapy for MSI-High dMMR Metastatic CRC Chalk Talk — Dr Ciombor ctDNA in Early and Metastatic CRC Chalk Talk — Dr Bekaii-Saab Gastric, Gastroesophageal and Esophageal Cancers Chalk Talk — Dr Ciombor Case: A woman in her late 60s with metastatic pancreatic cancer — Lowell L Hart, MD Case: A woman in her early 90s with metastatic cholangiocarcinoma — Dr Choksi CME information and select publications

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in acute myeloid leukemia, breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Neeraj Agarwal, Tanios Bekaii-Saab, Kristen Ciombor, Brad Kahl, Mark Levis, Ann Partridge, Mark Pegram, Daniel Petrylak, Noopur Raje, David Sallman, Lecia Sequist, David Spigel, Saad Zafar Usmani and Andrew Zelenetz.

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in breast cancer. Featuring perspectives from Drs Ann Partridge and Mark Pegram, including the following topics: Introduction Case: A woman in her late 40s with ER/PR-negative, HER2-positive metastatic breast cancer (mBC) — Syed F Zafar, MD Clinical Implications of the DESTINY-Breast03 Trial — Elizabeth Guancial, MD Case: A woman in her mid-70s with ER-positive, PR-negative, HER2-positive mBC with bone and brain metastases — Sunil Gandhi, MD DESTINY-Breast03 Trial Chalk Talk — Dr Pegram Postneoadjuvant/Adjuvant Neratinib for HER2-Positive Breast Cancer Chalk Talk — Dr Partridge Case: A woman in her early 50s with ER/PR-positive, HER2-negative mBC — Susmitha Apuri, MD Case: A premenopausal woman in her early 50s with ER/PR-positive, node-positive x 1 breast cancer — Raji Shameem, MD Case: A woman in her early 60s with ER/PR-positive breast cancer — Dr Apuri Genomic Assays in ER-Positive Breast Cancer Chalk Talk — Dr Pegram Selecting a First-Line CDK4/6 Inhibitor for ER-Positive Metastatic Breast Cancer Chalk Talk — Dr Partridge Case: A woman in her early 60s with asynchronous second primary triple-negative breast cancer (TNBC) — Mamta Choksi, MD KEYNOTE-522 Trial Chalk Talk — Dr Pegram OlympiA Trial Chalk Talk — Dr Partridge CME information and select publications

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in acute myeloid leukemia, breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Neeraj Agarwal, Tanios Bekaii-Saab, Kristen Ciombor, Brad Kahl, Mark Levis, Ann Partridge, Mark Pegram, Daniel Petrylak, Noopur Raje, David Sallman, Lecia Sequist, David Spigel, Saad Zafar Usmani and Andrew Zelenetz.

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in acute myeloid leukemia, breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Neeraj Agarwal, Tanios Bekaii-Saab, Kristen Ciombor, Brad Kahl, Mark Levis, Ann Partridge, Mark Pegram, Daniel Petrylak, Noopur Raje, David Sallman, Lecia Sequist, David Spigel, Saad Zafar Usmani and Andrew Zelenetz.

On today's episode of The PQI Podcast we welcome Dana Ingoglia RD, CSO, LDN , Natasha Khrystolubova RPh, BCOP, and Beth Wittmer RN, BSN, OCN, from Florida Cancer Specialists. Today we discuss symptom management and collaboration within the medically integrated team.You can find the website referenced in today's episode here:https://flcancer.com/oncology-nutrition/

info@podcastone.comf8db5ff4-7d09-4d63-97e2-4886f572f8a8Mon, 20 Sep 2021 11:44:56 PDT00:08:16The South Florida Sunday Podcast

Featuring perspectives from Drs Mamta Choksi and Chung-Han Lee, including the following topics: Introduction (0:00) Case: A man in his early 60s with metastatic renal cell carcinoma (RCC) treated with ipilimumab/nivolumab (2:38) Case: A man in his late 60s with metastatic RCC and high-risk oncolytic features who responded to ipilimumab/nivolumab (28:39) Case: A man in his mid-60s with Stage III RCC (42:54) CME information and select publications

Featuring a discussion with Drs Chung-Han Lee and Mamta Choksi on the management of renal cell carcinoma, moderated by Dr Neil Love.

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in breast cancer. Featuring perspectives from Drs Virginia Kaklamani and Nancy U Lin, including the following topics: Introduction  HER2-Positive Breast Cancer  ER-Positive, HER2-Negative Breast Cancer  Triple-Negative Breast Cancer  CME information and select publications

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in breast cancer, chronic lymphocytic leukemia and lymphomas, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Jonathan W Friedberg, Irene M Ghobrial, John V Heymach, Maha Hussain, Virginia Kaklamani, Nancy U Lin, Stephen V Liu, Sagar Lonial, Elizabeth R Plimack and Laurie H Sehn, moderated by Dr Neil Love.

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in multiple myeloma. Featuring perspectives from Drs Irene M Gobrial and Sagar Lonial, including the following topics: Introduction  Newly Diagnosed Multiple Myeloma  Relapsed Multiple Myeloma  Related Cases  CME information and select publications

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in breast cancer, chronic lymphocytic leukemia and lymphomas, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Jonathan W Friedberg, Irene M Ghobrial, John V Heymach, Maha Hussain, Virginia Kaklamani, Nancy U Lin, Stephen V Liu, Sagar Lonial, Elizabeth R Plimack and Laurie H Sehn, moderated by Dr Neil Love.

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in breast cancer, chronic lymphocytic leukemia and lymphomas, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Jonathan W Friedberg, Irene M Ghobrial, John V Heymach, Maha Hussain, Virginia Kaklamani, Nancy U Lin, Stephen V Liu, Sagar Lonial, Elizabeth R Plimack and Laurie H Sehn, moderated by Dr Neil Love.

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in breast cancer, chronic lymphocytic leukemia and lymphomas, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Jonathan W Friedberg, Irene M Ghobrial, John V Heymach, Maha Hussain, Virginia Kaklamani, Nancy U Lin, Stephen V Liu, Sagar Lonial, Elizabeth R Plimack and Laurie H Sehn, moderated by Dr Neil Love.

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in lung cancer. Featuring perspectives from Drs John V Heymach and Stephen V Liu, including the following topics: Introduction  First-Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Mutation  Immunotherapy Consolidation After Chemoradiation Therapy for Localized or Locally Advanced NSCLC  Extensive-Stage Small Cell Lung Cancer  Use of Targeted Treatment in NSCLC  CME information and select publications

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in lung cancer. Featuring perspectives from Drs Maha Hussain and Elizabeth R Plimack, including the following topics: Introduction  Renal Cell Carcinoma  Prostate Cancer  Urothelial Bladder Cancer  CME information and select publications

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in lung cancer. Featuring perspectives from Drs Jonathan W Friedberg and Laurie H Sehn, including the following topics: Introduction  Hodgkin Lymphoma  Chronic Lymphocytic Leukemia  Mantle Cell Lymphoma  Diffuse Large B-Cell Lymphoma  Follicular Lymphoma  CME information and select publications

Podcast guests' comments reflect their experiences and opinions and should not be used as a substitute for medical judgement. Important notice: NCODA has developed this PQI Podcast platform. This platform is intended as an educational aid and does not provide individual medical advice and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with any medication discussed in the platform and is not intended as a substitute for the advice of a qualified healthcare professional. The materials contained in this platform are for informational purposes only and do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA, which assumes no liability for and does not ensure the accuracy of the information presented. NCODA does not make any representations with respect to the medications whatsoever, and any and all decisions, with respect to such medications, are at the sole risk of the individual consuming the medication. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional.

info@podcastone.com10b7f514-0c56-490b-afc5-989ffd67328cThu, 20 May 2021 15:05:54 PDT00:05:31The South Florida Sunday Podcast

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, lung cancer, lymphomas and chronic lymphocytic leukemia and multiple myeloma. Featuring perspectives from Drs Arjun Balar, Johanna Bendell, Axel Grothey, Brad S Kahl, Shaji K Kumar, Kathleen Moore, Loretta Nastoupil, William K Oh, David M O'Malley, Robert Z Orlowski, Hope S Rugo, Gregory J Riely, David R Spigel and Sara M Tolaney, moderated by Neil Love, MD.

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, lung cancer, lymphomas and chronic lymphocytic leukemia and multiple myeloma. Featuring perspectives from Drs Arjun Balar, Johanna Bendell, Axel Grothey, Brad S Kahl, Shaji K Kumar, Kathleen Moore, Loretta Nastoupil, William K Oh, David M O'Malley, Robert Z Orlowski, Hope S Rugo, Gregory J Riely, David R Spigel and Sara M Tolaney, moderated by Neil Love, MD.

info@podcastone.co